JP2014129405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014129405A5 JP2014129405A5 JP2014043298A JP2014043298A JP2014129405A5 JP 2014129405 A5 JP2014129405 A5 JP 2014129405A5 JP 2014043298 A JP2014043298 A JP 2014043298A JP 2014043298 A JP2014043298 A JP 2014043298A JP 2014129405 A5 JP2014129405 A5 JP 2014129405A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- igf
- composition according
- patient
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 15
- 108010051696 Growth Hormone Proteins 0.000 claims 13
- 102100038803 Somatotropin Human genes 0.000 claims 13
- 239000000122 growth hormone Substances 0.000 claims 13
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 11
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 11
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 claims 5
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000036765 blood level Effects 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 102100020948 Growth hormone receptor Human genes 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 108010033419 somatotropin-binding protein Proteins 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 235000011888 snacks Nutrition 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 230000002618 waking effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68761705P | 2005-06-02 | 2005-06-02 | |
| US60/687,617 | 2005-06-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008514854A Division JP2008545752A (ja) | 2005-06-02 | 2006-06-01 | 成長障害を処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014129405A JP2014129405A (ja) | 2014-07-10 |
| JP2014129405A5 true JP2014129405A5 (enExample) | 2014-08-21 |
Family
ID=37482318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008514854A Pending JP2008545752A (ja) | 2005-06-02 | 2006-06-01 | 成長障害を処置するための方法 |
| JP2014043298A Pending JP2014129405A (ja) | 2005-06-02 | 2014-03-05 | 成長障害を処置するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008514854A Pending JP2008545752A (ja) | 2005-06-02 | 2006-06-01 | 成長障害を処置するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8158582B2 (enExample) |
| EP (1) | EP1901770B1 (enExample) |
| JP (2) | JP2008545752A (enExample) |
| ES (1) | ES2532089T3 (enExample) |
| WO (1) | WO2006130769A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0812768A2 (pt) | 2007-06-08 | 2014-12-02 | Massachusetts Inst Technology | Igf para o tratamento de síndrome de rett e transtornos sinápticos. |
| UA103104C2 (ru) | 2009-07-22 | 2013-09-10 | Ипсен Фарма С.А.С. | Аналоги инсулиноподобного фактора роста-1 (igf-1), содержащие аминокислотную замену в положении 59 |
| RU2558821C2 (ru) * | 2009-11-17 | 2015-08-10 | Ипсен Фарма С.А.С. | ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1 |
| JP6382187B2 (ja) * | 2012-06-21 | 2018-08-29 | フォスフォレックス，インコーポレーテッド | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| US20170368149A1 (en) * | 2014-12-16 | 2017-12-28 | Puretein Bioscience Llc. | Methods for increasing serum igf-1 in an animal |
| PL3672622T3 (pl) * | 2017-08-24 | 2024-04-02 | Genzyme Corporation | Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374620A (en) | 1990-06-07 | 1994-12-20 | Genentech, Inc. | Growth-promoting composition and its use |
| US5681814A (en) | 1990-06-07 | 1997-10-28 | Genentech, Inc. | Formulated IGF-I Composition |
| US5126324A (en) | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| SE9002731D0 (sv) | 1990-08-24 | 1990-08-24 | Kabivitrum Ab | Product comprising growth factor |
| TW267102B (enExample) | 1992-03-13 | 1996-01-01 | Ciba Geigy | |
| IL106546A0 (en) | 1993-08-01 | 1993-12-08 | Zvi Rozenberg | Apparatus for a bicycle and a two wheel vehicle |
| US5646113A (en) * | 1994-04-07 | 1997-07-08 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
| US5824642A (en) | 1994-04-07 | 1998-10-20 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
| US5741776A (en) | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
| DK2274978T3 (en) | 2003-09-12 | 2015-06-15 | Ipsen Biopharmaceuticals Inc | Methods of treating an insulin-like growth factor-I (IGF-I) deficiency |
| RU2558821C2 (ru) | 2009-11-17 | 2015-08-10 | Ипсен Фарма С.А.С. | ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1 |
-
2006
- 2006-06-01 US US11/915,978 patent/US8158582B2/en not_active Expired - Fee Related
- 2006-06-01 ES ES06784529.7T patent/ES2532089T3/es not_active Expired - Lifetime
- 2006-06-01 JP JP2008514854A patent/JP2008545752A/ja active Pending
- 2006-06-01 EP EP06784529.7A patent/EP1901770B1/en not_active Expired - Lifetime
- 2006-06-01 WO PCT/US2006/021282 patent/WO2006130769A2/en not_active Ceased
-
2012
- 2012-03-12 US US13/417,983 patent/US8440616B2/en not_active Expired - Fee Related
-
2014
- 2014-03-05 JP JP2014043298A patent/JP2014129405A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201892383A1 (ru) | Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина | |
| Csete | Basic science of frailty—biological mechanisms of age-related sarcopenia | |
| JP2017501381A5 (enExample) | ||
| JP2016539921A5 (enExample) | ||
| Díaz-Soto et al. | Efficacy and safety of long term treatment of unresponsive hypoparathyroidism using multipulse subcutaneous infusion of teriparatide | |
| JP2016516016A5 (enExample) | ||
| HRP20211768T1 (hr) | Liječenje postbarijatrijske hipoglikemije s antagonistima glp-1 | |
| Zhang et al. | Ghrelin attenuates intestinal ischemia/reperfusion injury in mice by activating the mTOR signaling pathway | |
| Padrutt et al. | Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats | |
| JP2018509419A5 (enExample) | ||
| JP2020502151A5 (enExample) | ||
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| Molfino et al. | The hunger hormone ghrelin in cachexia | |
| Bloomgarden | Exploring treatment strategies for type 2 diabetes | |
| RU2017126212A (ru) | Композиция | |
| D'Cruz et al. | Medical management of paediatric burn injuries: Best practice part 2 | |
| Hill et al. | Impact of ghrelin on body composition and muscle function in a long-term rodent model of critical illness | |
| Kyriakakis et al. | Lanreotide autogel in acromegaly–a decade on | |
| JP2015524441A5 (enExample) | ||
| JP2008545752A5 (enExample) | ||
| Cook | Growth hormone and estrogen: a clinician's approach | |
| JP2012517459A5 (enExample) | ||
| JP2016525530A5 (enExample) | ||
| Aviv et al. | Patterns of local site reactions to subcutaneous glatiramer acetate treatment of multiple sclerosis: a clinicopathological study | |
| Luk et al. | Pathology, pathophysiology, and treatment strategies of endocrine disorders and their cardiac complications |